FIBROCELL LIMITED

Company Registration Number:
00705725 (England and Wales)

Unaudited abridged accounts for the year ended 31 March 2024

Period of accounts

Start date: 01 April 2023

End date: 31 March 2024

FIBROCELL LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2024

Balance sheet
Notes

FIBROCELL LIMITED

Balance sheet

As at 31 March 2024


Notes

2024

2023


£

£
Fixed assets
Tangible assets: 3 182 215
Total fixed assets: 182 215
Current assets
Stocks: 250 275
Debtors:   1,736 1,441
Cash at bank and in hand: 11,468 10,437
Total current assets: 13,454 12,153
Creditors: amounts falling due within one year:   (72)
Net current assets (liabilities): 13,382 12,153
Total assets less current liabilities: 13,564 12,368
Provision for liabilities: (485) (497)
Total net assets (liabilities): 13,079 11,871
Capital and reserves
Called up share capital: 252 252
Profit and loss account: 12,827 11,619
Shareholders funds: 13,079 11,871

The notes form part of these financial statements

FIBROCELL LIMITED

Balance sheet statements

For the year ending 31 March 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 30 July 2024
and signed on behalf of the board by:

Name: B A Swift
Status: Director

The notes form part of these financial statements

FIBROCELL LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

FIBROCELL LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

2. Employees

2024 2023
Average number of employees during the period 1 1

FIBROCELL LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

3. Tangible Assets

Total
Cost £
At 01 April 2023 42,324
At 31 March 2024 42,324
Depreciation
At 01 April 2023 42,109
Charge for year 33
At 31 March 2024 42,142
Net book value
At 31 March 2024 182
At 31 March 2023 215